Novel Approaches to the Management of Patients with Gastrointestinal Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 15 March 2026 | Viewed by 252

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, 31008 Navarra, Spain
Interests: gastrointestinal oncology; gastric cancer; colorectal cancer; pancreatic cancer; immunotherapy; clinical trials; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medical Oncology, Gastrointestinal Unit, Cancer Center Clínica Universidad de Navarra, Madrid, Spain
Interests: gastrointestinal oncology; gastric cancer; colorectal cancer; immunotherapy; phase I clinical trials; neuroendocrine tumors; early drug development

Special Issue Information

Dear Colleagues,

Cancers of the digestive system are major contributors to global cancer-associated morbidity and mortality, accounting for 35% of cancer deaths annually. Although surgical resection remains the most common curative treatment for digestive cancers, the introduction of multimodal therapeutic approaches has improved the survival of many of these tumors. In addition, significant advancements in our understanding of the molecular biology underlying these tumors, including the interplay between cancer cells and the surrounding cancer microenvironment, have provided novel therapeutic alternatives and unprecedented insights into the genetic drivers of tumor progression, the mechanisms of therapy resistance, the role of targeted therapies, especially immunotherapy, and the key role of cfDNA in providing prognostic information. This knowledge is continuously translated into novel treatment concepts and targets, which are transforming the therapeutic landscape of these tumors. In this Special Issue, we will focus on novel approaches to the management of patients with esophageal, gastric, and colorectal cancers. This may include TNT approaches, the pharmacological management of these malignancies, including chemo-, targeted, and immunotherapy, innovative therapeutic strategies such as CAR-T cell therapy or novel antibody-drug conjugates, and the impact of artificial intelligence, the microbiome or omics on the design of alternative strategies.

Dr. Javier Rodríguez
Dr. Ignacio Matos García
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical management
  • gastric cancer
  • colorectal cancer
  • predictive factors
  • novel therapies
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 570 KiB  
Article
Neoadjuvant Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma: Long-Term Results and Statistical Algorithm to Predict Individual Risk of Relapse
by Miguel Ortego, Olast Arrizibita, Adriana Martinez-Lage, Ángel Vizcay Atienza, Laura Álvarez Gigli, Oskitz Ruiz, José Carlos Subtil, Maialen Zabalza, Victor Valentí, Ana Tortajada, María José Hidalgo, Onintza Sayar and Javier Rodriguez
Cancers 2025, 17(9), 1530; https://doi.org/10.3390/cancers17091530 - 30 Apr 2025
Viewed by 183
Abstract
Background: The purpose of this study was to evaluate the long-term outcomes of patients with locally advanced gastric adenocarcinoma (LAGC) intended to receive induction chemotherapy, chemoradiation and surgery and to develop an algorithm to estimate the individual risk of relapse in a population-based [...] Read more.
Background: The purpose of this study was to evaluate the long-term outcomes of patients with locally advanced gastric adenocarcinoma (LAGC) intended to receive induction chemotherapy, chemoradiation and surgery and to develop an algorithm to estimate the individual risk of relapse in a population-based setting. Methods: Patients with LAGC (cT3-4 and/or N+) were retrospectively evaluated. A pathological response was graded according to the Becker criteria. The nodal regression grade was assessed by a 4-point scale (A–D). A comprehensive analysis of 155 individual patient variables was performed, and logistic regression (LR) was utilized to develop a predictive model for relapse risk. Results: From 2010 to 2024, 48 patients were analyzed. After a median follow-up of 49 months (range, 12–212), the 5-year actuarial PFS and OS rates were 44% and 48%, respectively. Four variables were identified as the most relevant features for training the LR model. Scores for the model accuracy, sensitivity and specificity (mean +/− sd) were 0.79 +/− 0.12, 0.74 +/− 0.221 and 0.88 +/− 0.14, respectively. For a validation dataset, the figures were 0.78, 0.88 and 0.73, respectively. Conclusions: This neoadjuvant strategy seems to correlate with a favorable long-term outcome in a subset of intestinal-type LAGA patients who achieve ypN0 features. Full article
Show Figures

Figure 1

Back to TopTop